Skip to main content

Table 2 Association between ventriculomegaly and cerebrospinal fluid flow with clinical, cerebrospinal fluid and neuroimaging characteristics

From: Correlation of CSF flow using phase-contrast MRI with ventriculomegaly and CSF opening pressure in mucopolysaccharidoses

Characteristics

Ventriculomegaly

CSF stroke volume

Evans’ index

Third ventricle width (mm)

Callosal angle (°)

Aqueductal (ml/CC)

C2–C3 (ml/CC)

>0.3

n = 15

≤0.3

n = 28

p

>10

n = 14

≤10

n = 29

p

<90

n = 8

≥90

n = 35

p

>0.05

n = 11

≤0.05

n = 31

p

>0.5

n = 7

≤0.5

n = 35

p

Age (years)

9 (2–30)

12 (1–36)

0.483

10 (2–30)

12 (1–36)

0.577

9 (2–26)

12 (1–36)

0.502

6 (1–31)

12 (1–36)

0.229

12 (1–31)

10 (1–36)

0.774

Male sex

11 (73.3)

14 (50.0)

0.199

12 (85.7)

13 (44.8)

0.019

6 (75.0)

19 (54.3)

0.434

8 (72.7)

16 (51.6)

0.299

5 (71.4)

19 (54.3)

0.679

Type

  

0.709

  

0.373

  

0.333

  

0.183

  

>0.99

 I

4 (26.7)

8 (28.6)

 

3 (21.4)

9 (31.0)

 

2 (25.0)

10 (28.6)

 

3 (27.3)

8 (25.8)

 

2 (28.6)

9 (25.7)

 

 II

7 (46.7)

8 (28.6)

 

7 (50.0)

8 (27.6)

 

5 (62.5)

10 (28.6)

 

6 (54.5)

9 (29.0)

 

4 (57.1)

11 (31.4)

 

 III

1 (6.7)

4 (14.3)

 

2 (14.3)

3 (10.3)

 

1 (12.5)

4 (11.4)

 

2 (18.2)

3 (9.7)

 

1 (14.3)

4 (11.4)

 

 IV

2 (13.3)

7 (25.0)

 

1 (7.1)

8 (27.6)

 

0 (0.0)

9 (25.7)

 

0 (0.0)

9 (29.0)

 

0 (0.0)

9 (25.7)

 

 VI

1 (6.7)

1 (3.6)

 

1 (7.1)

1 (3.4)

 

0 (0.0)

2 (5.7)

 

0 (0.0)

2 (6.5)

 

0 (0.0)

2 (5.7)

 

Severe form

9 (60.0)

4 (14.3)

0.004

8 (57.1)

5 (17.2)

0.013

6 (75.0)

7 (20.0)

0.006

6 (54.5)

7 (22.6)

0.066

2 (28.6)

11 (31.4)

>0.99

Macrocephaly

9 (60.0)

5 (17.9)

0.008

8 (57.1)

6 (20.7)

0.035

5 (62.5)

9 (25.7)

0.089

6 (54.5)

7 (22.6)

0.066

2 (28.6)

11 (31.4)

>0.99

CI

10 (66.7)

8/27 (29.6)

0.027

10 (71.4)

8/28 (28.6)

0.019

6 (75.0)

12/34 (35.3)

0.056

6 (54.5)

11/30 (36.7)

0.476

4 (57.1)

13/34 (38.2)

0.421

eCSF protein

6/12 (50.0)

12/25 (48.0)

>0.99

5/12 (41.7)

13/25 (52.0)

0.728

3/7 (42.9)

15/30 (50.0)

>0.99

2 (18.2)

15/25 (60.0)

0.031

2/6 (33.3)

15/30 (50.0)

0.662

eCSF GAGs

8/12 (66.7)

13/25 (52.0)

0.491

9/12 (75.0)

12/25 (48.0)

0.166

5/7 (71.4)

16/30 (53.3)

0.674

8 (72.7)

13/25 (52.0)

0.295

4/6 (66.7)

17/30 (56.7)

>0.99

dPVS

14 (93.3)

15 (53.6)

0.015

14 (100.0)

15 (51.7)

0.001

7 (87.5)

22 (62.9)

0.240

11 (100.0)

17 (54.8)

0.007

7 (100.0)

21 (60.0)

0.075

eWML load

12/14 (85.7)

9 (32.1)

0.003

11/13 (84.6)

10 (34.5)

0.006

8 (100.0)

13/34 (38.2)

0.003

7 (63.6)

14 (45.2)

0.484

2 (28.6)

19 (54.3)

0.410

SCC

10 (66.7)

20 (71.4)

0.742

9 (64.3)

21 (72.4)

0.726

4 (50.0)

26 (74.3)

0.217

6 (54.5)

23 (74.2)

0.270

3 (42.9)

26 (74.3)

0.176

  1. Data are presented as median (minimum–maximum) or counts (percentages)
  2. Italic values indicate significance of p value (p < 0.05)
  3. p statistical significance, CSF cerebrospinal fluid, Severe form Hurler syndrome (MPS I) and severe form of MPS II, Macrocephaly +2SD or 98%, CI cognitive impairment (score < 70), eCSF protein elevated cerebrospinal fluid protein (>32 mg/dl), eCSF GAGs elevated CSF glycosaminoglycans (>250 ng/ml), dPVS dilated perivascular spaces (number ≥ 10), eWML load elevated white matter lesion load (>0.4 cm3), SCC spinal cord compression (absence of CSF in any direction and/or myelomalacia)